Top Key Companies for Nuclear Medicine Imaging Agents Market: GE HealthCare, Bracco Diagnostic, Guerbet, Mallinckrodt, Lantheus, Yantai Dongcheng, Foshan Rui Diao Pharmaceutical, Cardinal Health, Blue Earth Diagnostics, Bayer AG, Abx Advanced Biochemical, Eli Lilly and Company, Jubilant Pharma Limited, Navidea.
Global Nuclear Medicine Imaging Agents Market Size was estimated at USD 12564.96 million in 2022 and is projected to reach USD 14682.74 million by 2028, exhibiting a CAGR of 2.63% during the forecast period.
Global Nuclear Medicine Imaging Agents Market Overview And Scope:
The Global Nuclear Medicine Imaging Agents Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Nuclear Medicine Imaging Agents utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Nuclear Medicine Imaging Agents Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nuclear Medicine Imaging Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nuclear Medicine Imaging Agents market.
Global Nuclear Medicine Imaging Agents Market Segmentation
By Type, Nuclear Medicine Imaging Agents market has been segmented into:
Fluorine 18 Labeling
Carbon 11 Labeling
Nitrogen 13 Labeling
Oxygen 15 Labeling
Technetium 99 Labeling
Others
By Application, Nuclear Medicine Imaging Agents market has been segmented into:
Early Diagnosis
Clinical Stage
Treatment Evaluation
Regional Analysis of Nuclear Medicine Imaging Agents Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Nuclear Medicine Imaging Agents Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Nuclear Medicine Imaging Agents market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Nuclear Medicine Imaging Agents market.
Top Key Companies Covered in Nuclear Medicine Imaging Agents market are:
GE HealthCare
Bracco Diagnostic
Guerbet
Mallinckrodt
Lantheus
Yantai Dongcheng
Foshan Rui Diao Pharmaceutical
Cardinal Health
Blue Earth Diagnostics
Bayer AG
Abx Advanced Biochemical
Eli Lilly and Company
Jubilant Pharma Limited
Navidea
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Nuclear Medicine Imaging Agents Market by Type
5.1 Nuclear Medicine Imaging Agents Market Overview Snapshot and Growth Engine
5.2 Nuclear Medicine Imaging Agents Market Overview
5.3 Fluorine 18 Labeling
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Fluorine 18 Labeling: Geographic Segmentation
5.4 Carbon 11 Labeling
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Carbon 11 Labeling: Geographic Segmentation
5.5 Nitrogen 13 Labeling
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Nitrogen 13 Labeling: Geographic Segmentation
5.6 Oxygen 15 Labeling
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Oxygen 15 Labeling: Geographic Segmentation
5.7 Technetium 99 Labeling
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Technetium 99 Labeling: Geographic Segmentation
5.8 Others
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Others: Geographic Segmentation
Chapter 6: Nuclear Medicine Imaging Agents Market by Application
6.1 Nuclear Medicine Imaging Agents Market Overview Snapshot and Growth Engine
6.2 Nuclear Medicine Imaging Agents Market Overview
6.3 Early Diagnosis
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Early Diagnosis: Geographic Segmentation
6.4 Clinical Stage
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Clinical Stage: Geographic Segmentation
6.5 Treatment Evaluation
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Treatment Evaluation: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Nuclear Medicine Imaging Agents Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Nuclear Medicine Imaging Agents Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Nuclear Medicine Imaging Agents Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 GE HEALTHCARE
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 BRACCO DIAGNOSTIC
7.4 GUERBET
7.5 MALLINCKRODT
7.6 LANTHEUS
7.7 YANTAI DONGCHENG
7.8 FOSHAN RUI DIAO PHARMACEUTICAL
7.9 CARDINAL HEALTH
7.10 BLUE EARTH DIAGNOSTICS
7.11 BAYER AG
7.12 ABX ADVANCED BIOCHEMICAL
7.13 ELI LILLY AND COMPANY
7.14 JUBILANT PHARMA LIMITED
7.15 NAVIDEA
Chapter 8: Global Nuclear Medicine Imaging Agents Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Fluorine 18 Labeling
8.2.2 Carbon 11 Labeling
8.2.3 Nitrogen 13 Labeling
8.2.4 Oxygen 15 Labeling
8.2.5 Technetium 99 Labeling
8.2.6 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Early Diagnosis
8.3.2 Clinical Stage
8.3.3 Treatment Evaluation
Chapter 9: North America Nuclear Medicine Imaging Agents Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Fluorine 18 Labeling
9.4.2 Carbon 11 Labeling
9.4.3 Nitrogen 13 Labeling
9.4.4 Oxygen 15 Labeling
9.4.5 Technetium 99 Labeling
9.4.6 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Early Diagnosis
9.5.2 Clinical Stage
9.5.3 Treatment Evaluation
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Nuclear Medicine Imaging Agents Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Fluorine 18 Labeling
10.4.2 Carbon 11 Labeling
10.4.3 Nitrogen 13 Labeling
10.4.4 Oxygen 15 Labeling
10.4.5 Technetium 99 Labeling
10.4.6 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Early Diagnosis
10.5.2 Clinical Stage
10.5.3 Treatment Evaluation
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Nuclear Medicine Imaging Agents Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Fluorine 18 Labeling
11.4.2 Carbon 11 Labeling
11.4.3 Nitrogen 13 Labeling
11.4.4 Oxygen 15 Labeling
11.4.5 Technetium 99 Labeling
11.4.6 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Early Diagnosis
11.5.2 Clinical Stage
11.5.3 Treatment Evaluation
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Nuclear Medicine Imaging Agents Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Fluorine 18 Labeling
12.4.2 Carbon 11 Labeling
12.4.3 Nitrogen 13 Labeling
12.4.4 Oxygen 15 Labeling
12.4.5 Technetium 99 Labeling
12.4.6 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Early Diagnosis
12.5.2 Clinical Stage
12.5.3 Treatment Evaluation
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Nuclear Medicine Imaging Agents Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Fluorine 18 Labeling
13.4.2 Carbon 11 Labeling
13.4.3 Nitrogen 13 Labeling
13.4.4 Oxygen 15 Labeling
13.4.5 Technetium 99 Labeling
13.4.6 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Early Diagnosis
13.5.2 Clinical Stage
13.5.3 Treatment Evaluation
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Nuclear Medicine Imaging Agents Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Fluorine 18 Labeling
14.4.2 Carbon 11 Labeling
14.4.3 Nitrogen 13 Labeling
14.4.4 Oxygen 15 Labeling
14.4.5 Technetium 99 Labeling
14.4.6 Others
14.5 Historic and Forecasted Market Size By Application
14.5.1 Early Diagnosis
14.5.2 Clinical Stage
14.5.3 Treatment Evaluation
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Nuclear Medicine Imaging Agents Scope:
|
Report Data
|
Nuclear Medicine Imaging Agents Market
|
|
Nuclear Medicine Imaging Agents Market Size in 2025
|
USD XX million
|
|
Nuclear Medicine Imaging Agents CAGR 2025 - 2032
|
XX%
|
|
Nuclear Medicine Imaging Agents Base Year
|
2024
|
|
Nuclear Medicine Imaging Agents Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
GE HealthCare, Bracco Diagnostic, Guerbet, Mallinckrodt, Lantheus, Yantai Dongcheng, Foshan Rui Diao Pharmaceutical, Cardinal Health, Blue Earth Diagnostics, Bayer AG, Abx Advanced Biochemical, Eli Lilly and Company, Jubilant Pharma Limited, Navidea.
|
|
Key Segments
|
By Type
Fluorine 18 Labeling
Carbon 11 Labeling
Nitrogen 13 Labeling
Oxygen 15 Labeling
Technetium 99 Labeling
Others
By Applications
Early Diagnosis
Clinical Stage
Treatment Evaluation
|
